中药作为前列腺癌治疗选择:疗效与机制综述
本文系统综述前列腺癌发病机制,并基于近十年文献分析中药治疗前列腺癌的临床疗效与分子机制。中药可调节内环境、抑制肿瘤增殖转移、促进凋亡、调节自噬与铁死亡、逆转化疗耐药,并减轻放化疗副作用,但需大规模多中心研究支持。
要点
- 中药可作为前列腺癌辅助治疗,增强疗效、减轻毒性、延缓进展。
- 中药通过抑制增殖转移、促进凋亡、调节自噬与铁死亡等机制抗前列腺癌。
- 现有证据仍需大规模多中心研究验证中药在前列腺癌中的应用。
核心结论
- 前列腺癌发病涉及基因突变、雄激素信号异常、表观遗传改变、炎症及代谢重编程,机制尚未完全阐明。
- 中药通过调节细胞行为、改善症状、减少不良反应显著抑制前列腺癌进展。
- 中药临床应用仍需大规模多中心研究支持。
研究设计与样本
- 本文为系统综述,检索PubMed、Web of Science、EMBASE、Cochrane Library、万方数据库及中国知网(CNKI)。
- 检索关键词包括前列腺癌、发病机制、中草药、草药、中医药及中药活性成分等。
- 纳入标准包括近10年发表的原创临床研究、观察性研究、随机对照试验、荟萃分析及中药治疗前列腺癌机制研究。
主要发现
- 中药调节内环境以延缓进展、延长生存、改善生活质量、增强免疫防御并减轻放化疗副作用。
- 中药抑制肿瘤细胞增殖与转移、促进凋亡、调节自噬和铁死亡、逆转化疗耐药,发挥抗前列腺癌作用。
临床怎么用
- 中药可作为前列腺癌的辅助治疗选择,用于增强疗效、减轻毒性、延缓进展及改善生活质量。
- 临床应用中药时需结合患者具体情况,并关注其调节细胞行为及减轻放化疗副作用的作用。
局限性
- 前列腺癌发病机制尚未完全阐明,仍需进一步研究。
- 中药治疗前列腺癌的应用需大规模多中心研究支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Prostate Cancer (PCa) remains a leading malignancy in males, with significant morbidity and mortality. Despite advancements in treatment, challenges like resistance, recurrence, and metastasis persist. Traditional Chinese Medicine (TCM) offers a promising adjunctive approach, enhancing treatment efficacy, reducing toxicity, delaying progression, and improving quality of life. AIM OF THE STUDY: This study reviews PCa pathogenesis and evaluates the therapeutic potential of TCM through clinical efficacy data and mechanistic investigations. We further outline TCM's capacity to modulate PCa cellular dynamics through multi-scale biological interactions, establishing a framework for its application in PCa management. Our findings offer insights into TCM-based strategies for overcoming therapeutic limitations in prostate oncology. MATERIALS AND METHODS: This paper provides a systematic summary of PCa pathogenesis and analyzes the clinical efficacy and molecular mechanisms of TCM in treating PCa. Findings are based on searches using keywords such as 'prostate cancer,' 'pathogenesis,' 'Chinese herbal medicine,' 'herbal medicine,' 'traditional Chinese medicine,' and 'active components of Chinese medicine' in PubMed, Web of Science, EMBASE, Cochrane Library, Wanfang Database, and China National Knowledge Infrastructure (CNKI). INCLUSION CRITERIA: ① Original clinical studies, observational studies, RCTs, and meta-analyses related to the topic. ② Articles published in the last 10 years on PCa treatment and mechanisms in TCM. ③ Studies investigating the mechanisms, treatment strategies, or efficacy of Chinese medicine in PCa. ④ Research on the molecular mechanisms, therapeutic effects, or potential of Chinese herbs or components for PCa. EXCLUSION CRITERIA: ① Abstracts, conference proceedings, opinion pieces, or non-peer-reviewed articles. ② Studies with low methodological quality (e.g., lacking control groups or detailed drug dosages). ③ Irrelevant studies or those focusing on unrelated diseases. RESULTS: PCa pathogenesis involves gene mutations, androgen signaling abnormalities, epigenetic changes, inflammation, and metabolic reprogramming. TCM modulates the internal environment to delay progression, extend survival, improve quality of life, enhance immune defense, and alleviate chemotherapy and radiation side effects. TCM also inhibits tumor cell proliferation, metastasis, promotes apoptosis, regulates autophagy and ferroptosis, and reverses chemotherapy resistance, exerting anti-PCa effects through these pathways. CONCLUSIONS: PCa pathogenesis involves genetics, hormones, inflammation, and metabolism, and remains incompletely understood. TCM significantly inhibits PCa progression by regulating cell behavior, improving symptoms, and reducing adverse effects. However, large-scale, multi-center studies are needed to support its application.
引用
- Li S, Jing S, Zhou J, et al. Chinese medicines as therapeutic options for treating prostate cancer: Therapeutic effects and underlying mechanisms. J Ethnopharmacol. 2025. PMID: 40882785. doi:10.1016/j.jep.2025.120471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。